Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749861 | 0.93 | SOS1 (0.31) | SOS1SOS2 | |
| SCHEMBL14749867 | 0.82 | — | — | |
| SCHEMBL24659047 | 0.74 | SOS1 (0.33) | SOS1SOS2 | |
| SCHEMBL14749875 | 0.73 | CXCR4 (0.32) | ALDH1A1 | |
| SCHEMBL14072857 | 0.73 | — | — | |
| SCHEMBL8339642 | 0.70 | — | — | |
| SCHEMBL17762890 | 0.70 | — | — | |
| SCHEMBL12741070 | 0.70 | SOS1 (0.31) | SOS1SOS2 | |
| SCHEMBL1703805 | 0.67 | — | — | |
| SCHEMBL15534173 | 0.67 | SOS1 (0.30) | SOS1SOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250089-A1 | MAP4K3 SMALL MOLECULE DRUG INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-08-10 | — | — | US | disclosed |
| US-20130060023-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130060020-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130060024-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130060021-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130060022-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060021-A1 | Compounds useful for treating neurodegenerative disorders | SNCA, HTT, CLN6 | SOS1 4500/4885SOS2 4562/4885ALDH1A1 341/4885 |
| US-20130060020-A1 | Compounds useful for treating neurodegenerative disorders | SNCA, HTT, SMN1; SMN2 | SOS1 3800/4885SOS2 3931/4885ALDH1A1 818/4885 |
| US-20230250089-A1 | MAP4K3 SMALL MOLECULE DRUG INHIBITORS AND METHODS OF USE THEREOF | MAP4K3, MAP3K4, MAP3K3 | SOS1 3350/4885SOS2 2619/4885ALDH1A1 4400/4885 |
| US-20130060022-A1 | Compounds useful for treating neurodegenerative disorders | SNCA, HTT, SMN1; SMN2 | SOS1 4628/4885SOS2 4734/4885ALDH1A1 554/4885 |
| US-20130060023-A1 | Compounds useful for treating neurodegenerative disorders | SNCA, HTT, SMN1; SMN2 | SOS1 3800/4885SOS2 3931/4885ALDH1A1 818/4885 |
| US-20130060024-A1 | Compounds useful for treating neurodegenerative disorders | SNCA, HTT, SMN1; SMN2 | SOS1 4501/4885SOS2 4660/4885ALDH1A1 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.